NVCN.TO - Neovasc Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.05
-0.00 (-9.09%)
At close: 3:47PM EDT
Stock chart is not supported by your current browser
Previous Close0.05
Open0.05
Bid0.05 x 0
Ask0.05 x 0
Day's Range0.05 - 0.05
52 Week Range0.04 - 2.32
Volume359,818
Avg. Volume3,904,269
Market Cap93.761M
Beta4.30
PE Ratio (TTM)N/A
EPS (TTM)-0.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.57
  • CNW Group1 hour ago

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    NASDAQ, TSX: NVCN VANCOUVER , July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base ...

  • CNW Group7 days ago

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    NASDAQ, TSX: NVCN VANCOUVER , July 9, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group14 days ago

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany. This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.

  • CNW Group14 days ago

    Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement

    VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System. "This new base shelf prospectus will replace our existing base shelf prospectus that expires on July 9, 2018," commented Chris Clark, Neovasc's Chief Financial Officer. The base shelf prospectus and the Registration Statement, once clear and effective, respectively, will allow Neovasc to offer up to U.S.$100,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Microbix Biosystems, GeneNews, Neovasc and Trillium Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group25 days ago

    Tiara™ Featured in Live Case at 11th Annual TVT 2018

    VANCOUVER, June 21, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2018"). In a live case broadcast to the main arena of the conference, Dr. Anson Cheung, and Dr. John G. Webb of St. Paul's Hospital (Vancouver, Canada) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation. The Heart Team weighed in on all available treatment options and determined the Tiara device was the best option for this patient.

  • Baystreet26 days ago

    Stocks in play: Neovasc Inc.

    Announced the first U.S. patient has been implanted with a Neovasc Reducer™, a CE-Marked medical device ...

  • CNW Group26 days ago

    Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

    VANCOUVER, June 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. Dr. Koenig commented "This patient has severe coronary artery disease and has suffered from refractory angina for a few years. My experience with the Reducer during the procedure, was very positive.

  • CNW Grouplast month

    Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

    VANCOUVER, June 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the "Board") has elected Steve Rubin as Chairman of the Board, effective immediately. "I am honored to have the opportunity to work more closely with Fred and the rest of the Neovasc team as we advance the Company's development and commercial strategy for the Tiara and Reducer," stated Mr. Rubin.

  • Loss-Making Neovasc Inc (NASDAQ:NVCN) Expected To Breakeven
    Simply Wall St.last month

    Loss-Making Neovasc Inc (NASDAQ:NVCN) Expected To Breakeven

    Neovasc Inc’s (NASDAQ:NVCN): Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. The company’s loss has recently broadened since it announced a -US$22.91M loss inRead More...

  • CNW Grouplast month

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

    NASDAQ, TSX: NVCN VANCOUVER , June 4, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered ...

  • CNW Group2 months ago

    Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer

    VANCOUVER, May 25, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided highlights from EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC), which took place at the Palais des Congrès in Paris, France May 22-25. "We had a successful and engaging meeting with investigators in our Tiara-II trial regarding clinical results to-date, optimal screening process, best practices for implantation, and a direct comparison of published Tiara clinical results with results from mitral clipping procedures," commented Fred Colen, Neovasc's Chief Executive Officer. Dr. Anson Cheung also presented the latest clinical results of the Tiara valve during the Mitral Valve Replacement session, noting that 56 patients had been implanted to date and the 30-day survival rate was 94%, with trace or no remaining mitral regurgitation in most cases.

  • Baystreet2 months ago

    Stocks in play: Neovasc Inc.

    Announced that its management and board of directors urge the Company's shareholders of record to vote ...

  • CNW Group2 months ago

    Neovasc's Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

    VANCOUVER, May 15, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the "Board") urge the Company's shareholders of record to vote "FOR" the proposal authorizing the Board to effect a reverse stock split. "Remaining on the Nasdaq Capital Market ("Nasdaq") is a critical piece of the Company's turnaround strategy," commented Fred Colen, Neovasc's President and Chief Executive Officer. "Without reaching a minimum bid price above US$1.00 for a minimum of 10 consecutive days before July 2, 2018, the Company may be delisted from the Nasdaq, which would have serious consequences for the Company as further outlined in this press release.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Neovasc, Nuvo Pharmaceuticals, Baylin Technologies and Canopy Growth

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group2 months ago

    Neovasc Announces Results for the First Quarter 2018

    VANCOUVER, May 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced financial results for the quarter ended March 31, 2018 (all figures in U.S. dollars unless otherwise indicated). "Despite a challenging period for our shareholders, we are encouraged by our improved financial position through the receipt of $12.3 million in proceeds from investor-initiated exercises of Series C warrants that were issued during our November 2017 public offering," commented Fred Colen, Neovasc's Chief Executive Officer.

  • CNW Group2 months ago

    Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

    VANCOUVER, May 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules"). The Company received a letter from the Nasdaq in March 2018 notifying it that it was not in compliance with the minimum market value requirement set forth in Listing Rule 5550(b)(2).

  • CNW Group3 months ago

    Neovasc Provides a General Update, Announces Filing of Annual Report on Form 20-F and Sets First Quarter 2018 Financial Results Conference Call and Webcast

    VANCOUVER, April 30, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided a general corporate update, concurrent with filing its Annual Report on Form 20-F, to highlight the Company's progress over the last month and to confirm the date of the earnings call where these matters will be discussed further.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Neovasc, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Baylin Technologies

    NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants

    VANCOUVER, April 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and the Neovasc Reducer™ (the "Reducer") therapy for Refractory Angina, today announced that it has received US$7,132,488 in proceeds from investor initiated exercises of 4,885,266 of the Series C warrants (the "Series C Warrants") issued pursuant to the November 2017 underwritten public offering (the "2017 Public Transaction"). Each Series C Warrant may be exercised at an exercise price equal to US$1.46 (subject to adjustment) at any time prior to 11:59 p.m. (New York time) on November 18, 2019 for a Series C unit (a "Series C Unit"), with each Series C Unit being comprised of one common share of the Company (each, a "Common Share"), one Series A warrant (a "Series A Warrant") and one Series B warrant (a "Series B Warrant").

  • CNW Group4 months ago

    Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017

    NASDAQ, TSX: NVCN VANCOUVER , March 28, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral ...

  • PR Newswire4 months ago

    Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017

    NASDAQ, TSX: NVCN VANCOUVER , March 28, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group4 months ago

    Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

    VANCOUVER, March 23, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US $35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • PR Newswire4 months ago

    Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

    VANCOUVER, March 23, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US $35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • PR Newswire4 months ago

    Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast

    NASDAQ, TSX: NVCN VANCOUVER , March 21, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...